SEC Form 4 · accession 0001387131-15-003645
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Scott Slakter
Officer — Chief Executive Officer · Director
Period of report
Dec 15, 2015
Accepted (ET)
Dec 17, 2015 · 11:56 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Dec 15, 2015 | J | 497,859 | — | A | 697,865 | I | By SKS Ocular 1 LLC |
| Common Stock, par value $0.0001 per share | holding | — | — | — | 509,146 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1SKS Ocular 1 LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular 1 LLC. Pursuant to the acquisition agreement, among other things, SKS Ocular 1 LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestone 1 has been met and on December 15, 2015, the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC. The Reporting Person has investment and voting power with respect to the Common Stock held by SKS Ocular 1 LLC. Therefore, the Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular 1 LLC. The Reporting Person disclaims any beneficial ownership of the Common Stock directly owned by SKS Ocular 1 LLC except to the extent of his pecuniary interest therein.